Brief: Durect And Innocoll Announce A $136 Million U.S. Licensing Agreement For Posimir® (Bupivacaine Solution)

DURECT

22/12/2021 12:47

Dec 22 (Reuters) - DURECT Corp  DRRX.O :
    * DURECT AND INNOCOLL ANNOUNCE A $136 MILLION U.S. LICENSING
AGREEMENT FOR POSIMIR® (BUPIVACAINE SOLUTION)
    * DURECT CORP - INNOCOLL GRANTED EXCLUSIVE DEVELOPMENT AND
COMMERCIALIZATION RIGHTS TO POSIMIR IN UNITED STATES
    * DURECT CORP - DURECT TO RECEIVE NEAR-TERM UPFRONT CASH
PAYMENTS
TOTALING $6 MILLION, POTENTIAL ADDITIONAL MILESTONE PAYMENTS OF
UP TO $130 MILLION
    * DURECT CORP - DURECT TO RECEIVE TIERED LOW TO MID
DOUBLE-DIGIT
ROYALTIES BASED ON U.S. SALES

Source text for Eikon:  ID:nPnbGd3CNa 
Further company coverage:  DRRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))